Key result
Self-expandable valves linked to ~233% higher 1-month mortality vs balloon-expandable valves in small aortic annuli.
Why the study?
TAVI in patients with a small aortic annulus poses a substantial challenge, increasing the risk of patient-prosthesis mismatch and overall mortality.
Does transcatheter self-expandable valve compared to balloon-expandable valve improve clinical outcomes in patients with small and very small aortic annuli undergoing TAVI?
Observational (n=1,364)
Does transcatheter self-expandable valve compared to balloon-expandable valve improve clinical outcomes in patients with small and very small aortic annuli undergoing TAVI?
Absolute Event Rate: 2% vs 0.6%
p-value: p=0.048
In patients with small and very small aortic annuli undergoing TAVI, self-expandable valves were associated with higher 1-month mortality and major vascular complications compared to balloon-expandable valves.
May warrant caution with self-expandable valves in small-annuli TAVI; leaves open randomized confirmation of mortality difference.
BACKGROUND: The management of Transcatheter Aortic Valve Implantation (TAVI) patients with a small aortic annulus (SAA) postures a substantial challenge, increasing the risk of patient- prosthesis mismatch (PPM) and overall mortality. AIMS: This study aimed to compare the hemodynamic and clinical outcomes of transcatheter balloon-expandable valve (BEV) versus transcatheter self-expandable valve (SEV) in SAA. METHODS: was performed. RESULTS: The study included 1364 consecutive patients with SAA of (BEV n = 485; SEV n = 879) at a mean age of 82 ± 7 years, of whom the vast majority were female (83%). Propensity-matched groups comprised of 329 and 122 paired for the SAA and vSAA patients, respectively. As compared to BEV in the SAA and vSAA analyses, SEV showed lower rates of postprocedural of LBBB (32% vs. 22% and 41% vs. 22%; both p < 0.01, respectively), however, higher rates of major vascular complications (2% vs. 7% and 2% vs. 12%; both p < 0.01, respectively) and major or life-threatening bleeding but only in vSAA group (17% vs. 9.1%, p = 0.009). One-month mortality was higher in the SEV versus BEV in both SAA and vSAA comparisons (2% vs. 0.6%, p = 0.048 and 3% vs. 0%, p = 0.018; respectively). A nonsignificant trend of higher 5-year mortality was observed in univariate models, noted mainly in vSAA patients (22% vs. 19%, p = 0.385; 24% vs. 15%, p = 0.073). CONCLUSIONS: The present analysis observed higher rates of major vascular complications and 1-month mortality in SAA and vSAA treated with SEV. A similar nonsignificant trend toward long-term mortality for the vSAA group was observed and should be evaluated in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Itach et al. (2024) conducted an observational in Small aortic annulus requiring TAVI (n=1,364). Transcatheter self-expandable valve (SEV) vs. Transcatheter balloon-expandable valve (BEV) was evaluated on 1-month mortality in SAA (p=0.048). Transcatheter self-expandable valves were associated with higher 1-month mortality compared to balloon-expandable valves in patients with small aortic annuli (2% vs. 0.6%, p=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: